Fri, March 20, 2009
Thu, March 19, 2009
Wed, March 18, 2009
Tue, March 17, 2009
Mon, March 16, 2009
Sun, March 15, 2009
Fri, March 13, 2009
Thu, March 12, 2009
Wed, March 11, 2009
Tue, March 10, 2009
Mon, March 9, 2009
Fri, March 6, 2009
Thu, March 5, 2009
Wed, March 4, 2009
Tue, March 3, 2009
Mon, March 2, 2009
Fri, February 27, 2009
Thu, February 26, 2009
Wed, February 25, 2009
Tue, February 24, 2009
Mon, February 23, 2009
Sun, February 22, 2009
Fri, February 20, 2009
Thu, February 19, 2009
[ Thu, Feb 19th 2009 ]: Market Wire
Enzon Reports 2008 Results
Wed, February 18, 2009
Tue, February 17, 2009

Operations Executive Joins ReGen Biologics


  Copy link into your clipboard //health-fitness.news-articles.net/content/2009/ .. /operations-executive-joins-regen-biologics.html
  Print publication without navigation Published in Health and Fitness on , Last Modified on 2009-02-25 06:26:44 by Market Wire


HACKENSACK, N.J.--([ BUSINESS WIRE ])--ReGen Biologics (OTC: RGBO) ("ReGen") today announced the addition of Jay Flounlacker to the senior management team. He joins ReGen as the Senior Vice President, Administration. He will be responsible for coordinating operations across the Company among other senior executives to optimize Company resources to achieve training targets, sales and other goals.

His extensive healthcare background includes his most recent position as the Vice President for Service Delivery at DST Health Solutions, where he led a team of over 200 employees in the United States and India to provide implementation, consulting and technical support.

His experience also includes additional consulting and executive management positions at Epiphany Partners, Electronic Data Systems (EDS), First Consulting Group, APACHE Medical Systems, and Amisys Synertec.

Mr. Flounlacker previously worked with the ReGen management team on several consulting projects, and was involved with the Company's successful 510(k) application for the Menaflex™ collagen meniscus implant.

"We are extremely pleased to have Jay on the team again, this time on a full-time basis," said Gerald E. Bisbee, Jr., Ph.D., Chairman and CEO. "His expertise in project management and business process will be invaluable as we fully implement our Menaflex U.S. launch activities," Dr. Bisbee continued.

Mr. Flounlacker holds an Executive MBA from Loyola College, and a BA in English from the University of Maryland, where he served on the College of Arts and Humanities Alumni Board of Directors.

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's first approved product using its proprietary biological collagen scaffold technology is the Menaflex™ collagen meniscus implant, which is cleared for sale in Europe and other countries and marketed through ReGen's European subsidiary, ReGen Biologics AG. ReGen received FDA clearance in the U.S. for the Menaflex device in December 2008. Visit [ www.regenbio.com ] and [ www.menaflex.com ] for more information.


Publication Contributing Sources

Similar Health and Fitness Publications